Eli Lilly Alzheimer - Search News

Eli Lilly Alzheimer’s drug rejected

Wall Street Journal · 2d

England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug

Regulator cited significant uncertainties about the drug’s benefits, as well as the high costs to treat its severe side effects.

Reuters on MSN · 2d

UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.

Bloomberg L.P. · 2d

Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.

FierceBiotech23h

Eisai, Eli Lilly didn't disclose heightened brain injury risk to Alzheimer's trial patients: NYT

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

The Financial Express7h

Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection: GlobalData

There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

22h

Novo Nordisk's semaglutide could also be effective against Alzheimer's

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results